Objective: Surgical resection of asymptomatic primary colorectal cancer in patients presenting with synchronous unresectable metastatic disease is controversial. Concerns and controversies remain over combining cytotoxic chemotherapy with bevacizumab in this patient population. Methods: We identified medical records of 99 patients with synchronous metastatic primary colorectal cancer who received chemotherapy with bevacizumab as their initial treatment. The incidence of subsequent use of surgery and surgical outcomes were recorded. Patients were also assessed for overall survival. Results: Patients who received bevacizumab-containing chemotherapy for synchronous metastatic primary colorectal cancer were divided into the non-surgery and surgery groups according to the resection status of their asymptomatic primary tumor. In the non-surgery group, two patients (4.4%) underwent additional surgery, while three patients (5.7%) required surgery for rectovesical fistula in the surgery group. The median overall survival was 17 months for the non-surgery group (95% CI: 10.6 -23.3 months) and 23 months for the surgery group (95% CI: 21.3 -24.6 months; P ¼ 0.322). Conclusions: This study utilizing chemotherapy with bevacizumab did not result in an increased rate of morbidity related to the unresected primary tumor. Survival is not compromised by leaving the primary colon tumor intact.
INTRODUCTION
Unresectable metastatic colorectal cancer (CRC) is generally not curable with current treatment modalities. Management focusses on palliation and control of symptoms, control of tumor growth and prolongation of progression-free (PFS) and overall survival (OS). Routine non-curative resection of the primary tumor in patients with synchronous metastatic disease is usually not required (1 -4) . CRC patients with synchronous metastases may present with a variable degree of symptoms of their primary tumor, and a palliative resection of the primary tumor prior to the initiation of systemic treatment might be required in some, if not all, circumstances (5 -7) . Despite various reports of the safety of bevacizumab use in patients with synchronous metastatic disease with an asymptomatic primary colorectal tumor, many practicing clinicians are still concerned about the possibility of complications such as bleeding and perforation. Furthermore, controversy on the resection of primary tumor in patients with synchronous metastasized CRC continues in terms of OS benefit (1 -10) .
We conducted a retrospective study focussed on the effect of bevacizumab-based chemotherapy on the emergence of local complications of cancer treatment, such as obstruction, perforation and fistula formation, in patients with unresectable metastatic CRC and a synchronous asymptomatic primary tumor. The effect of surgery on the patient outcomes was also assessed.
PATIENTS AND METHODS
Medical records of 99 patients with unresectable metastatic CRC treated with bevacizumab-containing chemotherapy were retrospectively reviewed in three institutions between March 2006 and June 2010. All patients were asymptomatic at the initial consultation with regard to their primary tumors (i.e. no major bleeding, perforation, impending obstruction). Patients were assigned in two groups according to the presence or absence of primary colonic tumor resection: surgery vs. no surgery. All the patients had unresectable adenocarcinoma of the colon or the rectum and received chemotherapy consisting of bevacizumab in combination with capecitabine þ oxaliplatin (XELOX), (11) or bolus fluorouracil, leucovorin þ irinotecan (IFL), (12) or infusional fluorouracil, leucovorin þ irinotecan (FOLFIRI) (13) .
All patients had unresectable liver metastases at the initial consultation with regard to their primary tumors. The patients were deemed unresectable by the surgical team. The diagnosis of unresectability was based on the number, location and distribution of the lesions that would otherwise hamper resection with clear surgical margins. Other reasons for unresectability were the presence of extrahepatic disease, inadequate liver reserve following resection and unfit patients. The patients who had metastatectomy, local ablative therapy or chemoembolization therapy were excluded. Patients with CNS metastases, exclusive bone metastasis and other serious non-malignant disease were also excluded.
Statistical analyses were performed using the SPSS software version 15. The Kaplan -Meier survival estimates were calculated for PFS and OS. PFS was defined as the time elapsed from the initial diagnosis of unresectable metastatic colorectal cancer to disease progression or death from any cause. OS was defined as the time from the diagnosis of unresectable metastatic colorectal cancer to death or until the date of the last follow-up. A separate log-rank test was used to identify the independent effect of primary tumor resection on survival. The variables were investigated using visual (histograms, probability plots) and analytical methods (Kolmogorov -Smirnov/Shapiro -Wilk's test) to determine the distribution. Descriptive analyses presented using medians and interquartile range for the non-normally distributed and ordinal variables. Since the serum lactate dehydrogenase (LDH) measurements were not normally distributed, non-parametric tests were conducted to compare these parameters as well as the ordinal variables. The MannWhitney U test was used to compare LDH between the groups. Since age values were normally distributed, the Student's t-test was used to compare between groups. The proportion of patients with Stage IV colorectal cancer was presented by gender, presence of major morbidity events, carcinoembryonic antigen (CEA), anemia, LDH and anatomic localization using cross tabulations. The x 2 test or Fisher's exact test, where appropriate, were used to compare these proportions in different groups. A P-value of ,0.05 was considered to show a statistically significant result.
RESULTS

PATIENT CHARACTERISTICS
The characteristics of the patients [non-surgery (n ¼ 46) and surgery arm (n ¼ 53)] are listed in Table 1 . The median age 
SURGICAL INTERVENTIONS
Patients in the surgery group had total colectomy (n ¼ 2), right hemicolectomy (n ¼ 14), left hemicolectomy (n ¼ 9), sigmoid resection (n ¼ 8), low anterior resection (n ¼ 12), abdominoperineal resection (APR) (n ¼ 7) (Fig. 1) . All but seven patients with APR had intestinal continuity established. Of the non-surgery group, two patients (4.4%) required surgery down the road due to rectovesical fistula and primary tumor obstruction. Three patients (5.7%) in the surgery group required additional surgery for rectovesical fistula. Major morbidity rates were similar in the two groups (P ¼ 0.567). The incidence of anemia was not significantly different in the resected vs. unresected patients (P ¼ 0.957).
There was no episode of proximal colonic perforation secondary to distal obstructing carcinoma or of intractable bleeding that necessitated surgical intervention. The incidence of major complications in both the surgery and nonsurgery groups was not affected by clinical or laboratory variables such as age, anatomic location of primary tumor, CEA and LDH levels (data not shown). There was no immediate postoperative mortality. None of the patients became resectable following chemotherapy.
SURVIVAL
The median PFS was shorter in the non-surgery group compared with that in the surgery group (7 vs. 9 months, P ¼ 0.002) (Fig. 2) . The median OS for the entire patients that were diagnosed as unresectable metastatic colorectal cancer was 23 months (95% CI: 20.3 -25.6 months). The median OS for the nonsurgery group that were diagnosed as unresectable metastatic colorectal cancer was 17 months (95% CI: 10.6 -23.3 months), which is comparable to 23 months in the surgery group (95% CI: 21.3 -24.6 months; P ¼ 0.322) (Fig. 3) .
ADVERSE EVENTS
All patients were assessable for toxicity. There was no toxic death in all patients. Grade 3 and 4 treatment-related toxicities are listed in Table 2 . In the non-surgery group, the rates of Grade 3 and 4 toxicities were neutropenia, 15.2%; diarrhea, 6.5%; nausea/vomiting, 4.3% and asthenia 2.2%.The most common Grade 3 and 4 adverse events in the surgery group were neutropenia of 20.8%, diarrhea, 7.6%; nausea/ vomiting, 7.5% and asthenia, 3.8%. 
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DISCUSSION
The main finding of this study was the safety of bevacizumabcontaining chemotherapy combinations in the treatment of patients with intact primary tumor and synchronous metastatic CRC. All the patients had received upfront modern combination chemotherapy plus bevacizumab. The incidence of major complications related to the unresected primary tumor was low in these patients. In the non-surgery group, 44 patients (95.7%) never required surgery for primary tumorrelated symptoms. Only two patients (4.4%) required surgery for complications such as rectovesical fistula and obstruction. Of the surgery group, three patients (5.7%) required surgery for rectovesical fistula. When all patients are considered in both the groups, only 5% of the patients required surgery of the primary tumor due to complications. None of the 99 patients with synchronous metastases from CRC and unresected primary tumor was stented, radiated or operated initially.
No data from prospective randomized trials is available to assess the benefit of resection of the primary tumor in metastatic CRC patients with low or absent symptoms. Tebbutt et al. (14) have summarized the 10-year experience of patients at the Royal Marsden Hospital in London who had been treated with chemotherapy with or without palliative resection of the primary. Eighty-two patients received initial chemotherapy without surgery and 280 patients underwent surgery followed by chemotherapy. The incidences of peritonitis, fistula formation and intestinal hemorrhage were not significantly different in the resected group vs. unresected patients. Intestinal obstruction occurred in 13% of the groups. More recently, Poultsides et al.
(1) reported a prospectively maintained database including 233 consecutive patients with synchronous metastatic CRC and an intact primary tumor who were treated with chemotherapy containing oxaliplatin or irinotecan as the initial therapy. Of these, 217 (93%) never required surgical palliation of their primary tumor. Sixteen patients (7%) required urgent surgery for obstruction or perforation, 10 patients (4%) required nonsurgical intervention (i.e. stent or radiotherapy) and 213 (89%) never required any direct symptomatic management for their intact primary tumor.
Our study examined several markers representative of tumor burden such as CEA, LDH and clinical variables such as age, anatomic location and anemia. We did not find any association with primary tumor complications. The location of the primary tumor in the rectum, as opposed to the colon, was not associated with a higher incidence of late surgery intervention. We were interested in examining whether this initial non-operative strategy was associated with a detrimental effect on survival. We did not observe any negative effect of non-surgical intervention on survival among asymptomatic patients. Chemotherapy plus bevacizumab for patients with unresectable metastatic CRC and a synchronous asymptomatic primary tumor does not appear to be associated with worse survival. We are aware of the drawbacks of a retrospective comparison. It is not possible to totally NCT-CTC, National Cancer Institute Common Toxicity Criteria.
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In conclusion, current evidence does not support routine palliative resection of the primary tumor in patients with synchronous metastatic disease. Our results are in accordance with the literature that shows safety of bevacizumab in metastatic patients with intact primary colonic tumors. In these patients who did not undergo resection of the primary, the rate of unplanned urgent surgical interventions and complications are relatively low which does not warrant routine palliative surgery. With regard to survival, we cannot draw firm conclusions based on retrospective data. Prospective randomized studies are required to address this controversy.
